Blog
RSS FeedPosted by Michael Wonder on 08 Feb 2024
Knight Therapeutics announces launch of Bijuva in Canada
6 February 2024 - Knight Therapeutics announced today the launch of Bijuva (oestradiol and progesterone) capsules in Canada. ...
Posted by Michael Wonder on 05 Feb 2024
Sumitomo Pharma and Pfizer Canada announce availability of Myfembree in Canada
31 January 2024 - In partnership with Sumitomo, Pfizer is proud to announce that supply of Myfembree (relugolix 40 mg, estradiol ...
Posted by Michael Wonder on 27 Jul 2023
New Brunswick to publicly reimburse Albrioza for the treatment of ALS
24 July 2023 - New Brunswick lists Albrioza on its drug benefit formulary, becoming the fourth province to provide public ...
Posted by Michael Wonder on 27 Jul 2023
British Columbia to publicly reimburse Albrioza for the treatment of ALS
19 July 2023 - Amylyx Pharmaceuticals Canada announced today that the Company has entered into a Product Listing Agreement with British ...
Posted by Michael Wonder on 29 Jun 2023
Ontario to publicly reimburse Albrioza for the treatment of ALS
28 June 2023 - Ontario lists Albrioza on its drug benefit formulary, becoming the first province to publicly reimburse Albrioza, ...
Posted by Michael Wonder on 15 Jun 2023
Amylyx Pharmaceuticals completes negotiation process and signs letter of intent with the pCPA for Albrioza for the treatment of ALS
15 June 2023 - Amylyx will now work with federal, provincial, and territorial drug plans to ensure public coverage is available ...
Posted by Michael Wonder on 09 Sep 2022
B.C. family grateful for expanded funding to cystic fibrosis drug, but questions why it took so long
7 September 2022 - B.C. is last Canadian jurisdiction to fund Trikafta for patients with cystic fibrosis age 6 to 11. ...
Posted by Michael Wonder on 07 Jul 2022
Vertex announces letter of intent with the pan-Canadian Pharmaceutical Alliance for public reimbursement of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 and older
7 July 2022 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...
Posted by Michael Wonder on 24 Feb 2022
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Ontario, Manitoba and New Brunswick
24 February 2022 - Private insurance coverage across Canada exceeds 90%. ...
Posted by Michael Wonder on 15 Dec 2021
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Quebec and Nova Scotia
15 December 2021 - Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. ...
Posted by Michael Wonder on 03 Nov 2021
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Alberta
3 November 2021 - First provincial public listing secured for both asthma medications. ...
Posted by Michael Wonder on 20 Sep 2021
Vertex announces letter of intent with pan-Canadian Pharmaceutical Alliance for public reimbursement of CFTR modulators Extended to Include Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
17 September 2021 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...
Posted by Michael Wonder on 21 Aug 2021
Cystic fibrosis patients, advocates urge Ontario government to provide ‘miracle drug’ funding
20 August 2021 - An Ontario teen living with Cystic Fibrosis and her mother are hoping to shine a light ...
Posted by Michael Wonder on 14 Aug 2021
Halifax man devastated after insurer reverses decision to cover $25,000 cystic fibrosis drug
13 August 2021 - Stefan Strecko says he's pleaded with Canada Life to cover cost of 'miracle' drug. ...
Posted by Michael Wonder on 31 Jul 2021
Frustrated cystic fibrosis patient speaks out after drug coverage denial
30 July 2021 - Twenty eight year old cystic fibrosis patient Stefan Strecko says he went from jubilation to devastation ...